Biora Therapeutics

Biora Therapeutics, founded in 2010 as Ascendant MDx, Inc. and later known as Progenity, Inc. before adopting its current name in 2022, specializes in developing smart-pill technologies aimed at delivering precise doses of medication to specific sites within the body. The company introduced the NaviCap™ Targeted Oral Delivery Platform, designed to treat inflammatory bowel disease by delivering therapeutics directly to the large intestine. Additionally, Biora developed the BioJet™ Systemic Oral Delivery Platform, which offers needle-free, oral delivery of large molecules, potentially replacing injections for better management of chronic diseases. Biora’s BioJet platform has shown promising results, with an average bioavailability of 20-37% for GLP-1 receptor agonists in animal studies, compared to less than 1% for currently marketed oral tablets. The company collaborates with AstraZeneca and Ionis Pharmaceuticals to evaluate the BioJet platform for their molecules. Biora has conducted studies with over 40 participants using the NaviCap device, demonstrating its potential to deliver therapeutics directly to disease sites in the gastrointestinal tract. The company underwent a strategic transformation in 2021 to focus on its innovative therapeutics pipeline and went public on June 19, 2020. Biora Therapeutics also provides comprehensive health benefits and support for fertility treatments for its employees.